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ABSTRACT
Objectives: The objectives of the study were to ascertain the efficacy of probiotics along with antimicrobials in the treatment of vulvovaginitis and to 
evaluate the rate of recurrence.
Methods: The study was done on 60 patients who were randomly selected and divided into two groups of 30 each. Prior permission from the 
Institutional Ethics Committee and higher authorities was obtained before conducting the study. One group received standard treatment including 
antibacterial, antiviral, and antifungal as per the gynecologist discretion and in other group along with standard treatment, probiotic capsules 
containing combination of Saccharomyces boulardii, Lactobacillus sporogenes (50 million), Streptococcus faecalis (30 million), Clostridium butyricum 
(2 million), and Bacillus mesentericus (1 million) given orally twice daily and followed up for a period of 3 months. The drugs were started on the 
5th day after menstruation taking starting of the bleeding as day 1.
Results: The parameters compared were symptoms and signs (significantly reduced – p-value), clue cells (significantly reduced in number), and 
recurrence rates (significantly reduced), in 80% of patients smears which were not consistent with BV. Maximum number of patients showed negative 
KOH mount (71.5%), saline wet mount was negative in 80% of patients in antimicrobial agents + probiotics group.
Conclusion: From the present interventional study, probiotics along with antimicrobial agents showed better improvement than antimicrobial agents 
alone. Hence, supplementation of probiotics along with antimicrobial agents provides better efficacy than antimicrobial agents alone in treating 
vulvovaginal infections.
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INTRODUCTION
Female lower genital tract, consisting of vagina and ectocervix, 
is biological niche where numerous aerobic and anaerobic 
microorganisms coexist in a dynamic balance. In fertile, premenopausal 
healthy women, the vaginal ecosystem is dominated by lactobacilli (L) 
species but a diverse array of other bacteria can be present in much 
lower numbers. L. crispatus, L. inners, L. jensenii, and L. gasseri are the 
predominant vaginal Lactobacillus species. Lactobacilli are implicated 
in regulating the normal vaginal microbiota by preventing overgrowth 
of pathogenic bacteria and opportunistic organisms [1].
Vulvovaginitis is defined as an inflammation of the vulva and vagina. It 
is the most common gynecological condition constituting about 25% of 
outpatients. The common forms of infectious vulvovaginitis are bacterial 
vaginosis (40–50%), candidiasis (20–25%), and trichomoniasis 
(15–20%) all with high rates of recurrence [2,3]. Bacterial vaginosis 
(BV) is one of the most common causes of genital discomfort in women, 
affecting about 19–24% in reproductive age group [4]. The prevalence 
of bacterial vaginosis varies in different parts of the world and it is 
higher in developing countries [5]. It is believed to occur as a result 
of an imbalance in the normal vaginal microbiota and is characterized 
by reduction in native lactobacilli and subsequently replaced by 
anaerobic bacteria [6,7]. Up to 10–15% of patients fail to respond to 
initial antimicrobial therapy and recurrence rates are significant (up to 
80%) and requiring repeated administration of antimicrobial agents. 
Such repeated exposure increases the risk of emergence of resistant 
strains, alteration of microbiota, and possible persistence of bacterial 
vaginosis associated pathogens [4]. Vulvovaginal candidiasis (VVC) 
is estimated to be the second most common form of vaginitis after 
bacterial vaginosis [8]. Although antifungal agents are quite effective in 
VVC, resistance to the drugs is increasing. In addition, drugs may reduce 
the normal protective vaginal flora to increase the risk of recurrent 
infections and can also cause many adverse effects [9,10].
As antimicrobial treatment of urogenital infections is not always 
effective and problems remain due to bacterial and yeast resistance, 
recurrent infections, as well as side effects of drugs, it is no surprise 
that alternative remedies are of interest to patients and health 
caregivers [11]. Under normal physiological setting, the patient’s own 
lactobacilli would come back after antimicrobial therapy and colonize 
the vagina, thereby conferring some protection from infection. The 
additional use of probiotics is designed to enhance this process [12]. 
This led to the idea of replacing the depleted lactobacilli using probiotic 
strains as a therapeutic approach.
METHODS
This clinical study was carried out in the department of pharmacology 
and obstetrics and gynecology, of a tertiary care teaching hospital of 
Central Karnataka over the period of one and half year.
The study included 60 patients, divided into two groups of 30 patients 
each. After obtaining ethical committee clearance from the Institutional 
Ethical Review Board, one group received standard regular treatment 
(the standard regular treatment may include antibacterial, antiviral, 
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and antifungal as per the gynecologist discretion) and in other 
group along with standard treatment, probiotic capsules containing 
combination of Saccharomyces boulardii, Lactobacillus sporogenes 
(50 million), Streptococcus faecalis (30 million), Clostridium butyricum 
(2 million), and Bacillus mesentericus (1 million) given orally twice daily 
for 1 month as add on treatment and follow-up was done for a period 
of 3 months. The drugs were started on the 5th day after menstruation 
taking starting of the bleeding as day 1. Informed consent was taken 
from all the patients. Statistical analysis was done using Student’s t-test.
n=60, consisting of two groups.
Group 1 = Antimicrobial agents alone and Group 2 = Antimicrobial 
agents + Probiotics capsules
Inclusion criteria
The following criteria were included in the study:
1. Female patients aged between 18 and 45 years (mean age 35 years)
2. Patients willing to give written informed consent
3. Clinical diagnosis of vulvovaginitis confirmed by any one of the tests 
such as Amsel’s criteria, Nugent score, KOH wet mount test, and saline 
wet mount test
4. Presence of at least one vulvovaginal symptom (vulvovaginal itching, 
white discharge per vagina, burning, and irritation) or at least one 
vulvovaginal sign (vulvovaginal erythema, edema, and excoriation)
5. Patients who were newly diagnosed and/or recurrent vulvovaginitis 
not treated in the previous 1 month.
Exclusion criteria
The following criteria were excluded from the study:
1. Pregnant or nursing women
2. Patient menstruating at the time of diagnosis
3. Usage of antibacterial drugs either systemically or intravaginally 
within the past 2 weeks
4. Patients already on medications for vulvovaginitis
5. Patients taking immunosuppressive or immunostimulating 
medications and systemic corticosteroids within 3 months before 
study
6. Patients involved in any other study in previous 1 month
7. Patients with comorbid conditions such as diabetes mellitus and 
sexually transmitted diseases such as gonorrhea, syphilis, chlamydia, 
and AIDS
8. Patients with a history of allergy to metronidazole, clotrimazole, and 
clindamycin
9. After history, detailed systemic and local examination including per 
speculum and per vaginal examination was done to know the type 
of discharge and other signs of vaginal infection by gynecologist.
Specimen collection
Vaginal discharge is collected from the posterior fornix with the help of 
sterile swab and the following tests were done:
Gram staining, KOH preparation, and saline wet mount.
Efficacy parameters [13]
1. Vaginal discharge by participant report: The grading was given in 
the following manner.
Grade 0 = Participants usual amount of discharge regardless of color or 
quantity (Normal discharge)
Grade 1 = Mild-moderate increase in amount above participant baseline 
– no sanitary protection is required (Mild discharge)
Grade 2 = Profuse increase in discharge requiring pad use or other 
hygienic intervention (Moderate discharge).
2. Dysuria – The grading was given in the following manner.
Grade 0 = None
Grade 1 = Superficial only
Grade 2 = Deep ± superficial
Grade 3 = Inability to void due to pain.
3. Dyspareunia – The grading was given in the following manner.
Grade 0 = None
Grade 1 = Pain causing no or minimum interference with sexual 
dysfunction
Grade 2 = Pain causing greater than minimal interference with sexual 
dysfunction
4. Vulval/Vaginal Itching – The scoring was given in the following 
manner.
Grade 0 = None
Grade 1 = Itching causing no, mild, or moderate interference with usual 
social and functional activities
Grade 2 = Itching causing inability to perform usual social and functional 
activities, may require intervention such as antihistamine or bathing 
to provide relief.
5. Vaginal discharge as reported by clinician [13]:
Grade 0 = Slight amount of discharge, any color
Grade 1 = Mild-moderate increase in amount
Grade 2 = Significant increase in amount with pooling in vagina examination.
1. Vaginal erythema:
Grade 0 = None
Grade 1 = Erythema covering < 50% of vaginal surface
Grade 3 = Erythema covering > 50% of vaginal surface.
2. Vaginal tenderness [13]:
Grade 0 = None
Grade 1 = Mild tenderness
Grade 2 = Moderate tenderness
Grade 3 = Severe tenderness.
Types of outcome measures




1. Nugent score – 1= Smear not consistent with bacterial vaginosis and 
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Fig. 2: Symptoms presentation
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symptoms, signs, Nugent scoring, and recurrence rate over the period 
of 3 months. Patients in both the groups received antimicrobial agents 
according to gynecologist discretion except the second group where 
along with the antimicrobial agents patients also received probiotics 
capsules twice daily for 30 days.
The study is suggestive of useful effects of probiotics supplementation 
in the treatment of VVC (Table 1). Even though treatment of yeast 
vaginitis, mainly with topical antimycotic drugs, is practically effective, 
recurrences are very frequent. Resistance to these drugs is growing 
because many women self-diagnose, self-treat, and option of over-the-
counter antifungal medications [14]. Normal vaginal microenvironment 
is largely populated by Lactobacillus species, which tend to keep a 
check on the growth of other bacterial species. This domination of 
lactobacilli and their potential capability to resist VVC gave rise to the 
concept of oral or vaginal instillation of probiotic Lactobacillus strains 
to restore the vaginal microbiotic equilibrium [10]. The results of study 
by Martinez et al. indicate that probiotics can be successfully used in 
treatment of Candida infections may be because of inhibition of the 
growth of Candida albicans in the vagina and strengthening of the 
immune system in the vagina, small bowel, and colon and reduction of 
fungi in the rectum and vagina [15].
In the present study, it is seen that in antimicrobial agents + probiotic 
group significant number of patients were negative for saline wet mount 
(80%) after treatment period. This is indicative of beneficial effects of 
probiotics in Trichomonas infections. p-value was significant (Table 2).
In the present study, the number of patients positive for clue cells was 
significantly less (15.3%) in antimicrobial agents + probiotics group 
(Table 3). We also compared mean value of Nugent scoring using 
independent sample “t-test.” There was a significant reduction in the 
mean value in antimicrobial agents + probiotics group (Table 4) and 
the mean difference is also very high and is highly significant (Table 5). 
We got significant p-value after applying unpaired “t-test” to Nugent 
scoring in between the groups. There was a significant increase in the 
number of patients with smear not consistent with BV (Table 6) in 
antimicrobial agents + probiotics group at the end of follow-up period 
which is similar to a study conducted by Anukam, where efficacy of 
combining probiotics or placebo with oral metronidazole was assessed 
in women aged 18–44 years. Study conducted by Bradshaw et al., using 
oral metronidazole 400 mg BD for 7 days followed by vaginal pessary 
containing L. acidophilus, reported similar results [1] At the end of 
follow up period symptoms and signs were significantly reduced in 
probiotics plus antibiotics group (Tables 7 and 8) similar results were 
found in a study done by Martinez et al.[9].
Prevention of recurrent BV in healthy women is an important issue 
In the present study reccurence rate was significantly reduced in 
probiotic plus antimicrobial agent group (Table 9) similar findings 
were noted in Mastromarino et al. study. [1] In majority of trials, the 
route of Lactobacillus was intravaginal. However, some investigators 
reported repopulation of vagina with oral probiotics. This was based 
on the observation that pathogens can pass from the gut into the 
urogenital system and recovery of lactobacilli from vagina after their 
oral administration [1].
As antimicrobial treatment of urogenital infections is not efficient for 
all time and troubles remain due to bacterial and yeast resistance, 
recurrent infections, as well as side effects of drugs, it is no surprise 
that alternative remedies are of interest to the patients and their health 
caregivers. One of the reasons for recurrent infection may be abolition 
of the commensal microorganisms in the vagina by the antimicrobials, 
Table 2: Saline wet mount at the end of follow-up




Antimicrobial agents alone 7 (70) 3 (30) 10
Antimicrobial agents + Probiotics 2 (20) 8 (80) 10
Total 9 11 20
Pearson Chi‑square value – 5.051. P=0.025 (p≤0.05, significant P value)
Table 4: Independent sample “t-test” – Nugent score at 90 days
Groups N Mean Std. deviation Difference t Df p-value
Antimicrobial agents alone 13 5.8462 2.51151 −4.15385 4.174 24 0.000
Antimicrobial agents + Probiotics 13 1.6923 2.56205
Table 1: KOH mount at the end of follow-up period
KOH mount Antimicrobial agents 
alone (%)




5 (71.4) 2 (28.5)
Table 3: Presence of clue cells at the end of 90 days
Clue cells Antimicrobial 
agents alone (%)
Antimicrobial agents + 
Probiotics (%)
90 days (end of 
follow-up period)
6 (46.1) 2 (15.3)
2. Clue cells – 1 =Absent and 2 =present
3. KOH mount – 1 = Negative for Candida and 2 = Positive for Candida
4. Saline wet mount – 1= Negative for Trichomonas and 2 = Positive for 
Trichomonas
Secondary outcome measures
●	 Symptoms as reported by the patient.
1 = Improvement of symptoms
2 = No improvements
●	 Clinical cure as reported by the physician or investigator.
1 = Improvement in signs
2 = No improvement in signs
●	 Persistence or recurrence of bacterial vaginosis at follows up (from 
30 days post-treatment)
1 = Smear consistent with bacterial vaginosis
2 = Smear not consistent with bacterial vaginosis
RESULTS
The results are based on data collected having demographic profile, 
pharmacological treatment prescribed, and clinical outcome.
There was no significant difference in the mean age between the two groups. 
Fig. 1 shows that 53% of patients were between 31 and 40 years age group and 
34% were between 21 and 30 years age group, indicating that vulvovaginal 
infections are more common in reproductive age groups (18–45 years).
The independent sample ‘t’ test for nugent’s score at the end of 90 days 
showed significant ‘P’ value(P<0.00) (Table 1). The saline wet mount 
at the end of followup on applying pearson chi-square test showed 
significant results (P<0.005)(Table 2). KOH mount at the end of followup 
was only 2% (28.5%) with probiotics and antimicrobial group (Table 3).
DISCUSSION
Efficacy of oral supplementation of probiotics along with antimicrobial 
agents is determined by assessing the patients for improvement of 
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thereby rising vulnerability to recolonization by pathogens. This is one 
of the main reasons to reestablish the commensal bacteria as a way to 
lower the risk of reinfection [1].
CONCLUSION
At the end of 3 months follow-up, probiotics along with antimicrobial 
agents showed significant improvement in symptoms and signs, Nugent 
score was towards normal, KOH mount and saline wet mount tests were 
negative, and decreased recurrence rate. Hence, oral supplementation of 
probiotics along with antimicrobial agents showed better efficacy. The 
use of probiotics to prevent infection has a good rationale and anexcellent 
safety record, but so far only a few strains have been clinically proven 
to be effective, in particular to prevent BV. It is criticallyimportant that 
strains be characterized and tested clinically using the delivery system 
of choice (oral, vaginal, dried powder, or in suspension).
The value of probiotics supplementation in vaginal infections other 
than candidiasis, bacterial vaginosis, and trichomoniasis needs to be 
explored. Many more studies are needed to optimize the defensive 
properties of the vaginal microbiota but the potential remains that 
health of many women can be improved by probiotics intervention [1].
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Table 8: Signs as reported by the physician at the end of 90 days
Signs Present Absent
Antimicrobial agents alone 60 40
Probiotics + Antimicrobial agents 20 80





Antimicrobial agents alone 63.30 36.70
Probiotics + Antimicrobial 
agents
20 80





Antimicrobial agents alone 66.60 33.40
Probiotics + Antimicrobial agents 16.60 83.40
Table 5: Interpretation of Nugent scoring using independent sample “t-test”
Groups Mean N Std. deviation Mean difference T Df p-valve
Antimicrobial agents alone
Pair 1
Nugent0 9.15 13 1.345 3.308 6.813 12 <0.001
Nugent90 5.85 13 2.512
Antimicrobial agents + Probiotics
Pair 1
Nugent0 9.0 13 1.291 7.308 10.417 12 <0.001
Nugent90 1.69 13 2.562
Table 6: Interpretation of Nugent scoring at the end of 90 days
Nugent’s score at the 
end of 90 days
Smear 
consistent with 
BV (%)
Smear not 
consistent with 
BV (%)
Antimicrobial agents 
alone
53.80 46.20
Probiotics + 
Antimicrobial agents
15.40 84.60
